There were 1,012 press releases posted in the last 24 hours and 221,566 in the last 365 days.

The Conjugated Monoclonal Antibodies Industry Grows With The Increasing Popularity And Potential Of Its Products

Conjugated Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030

Conjugated Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030

The Business Research Company’s Conjugated Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030

LONDON, GREATER LONDON, UK, April 7, 2021 /EINPresswire.com/ -- Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports

The increasing popularity and therapeutic potential of conjugated monoclonal antibodies, especially antibody-drug conjugates, is expected to drive the conjugated monoclonal antibodies market over the forecast period. Antibody-drug conjugates (ADCs) are a class of therapeutics consisting of monoclonal antibodies (MAbs) clubbed with highly potent cytotoxic drugs through a linker to kill the antigen-expressing tumor cells, predominantly used in the treatment of cancer. The U.S. Food and Drug Administration approved only five antibody-drug conjugates drugs from 2000 to 2018 and in 2019, it approved three antibody-drug conjugates drugs, indicating that the increased number of approvals is directly proportional to the use of conjugated monoclonal antibodies mainly in the field of cancer. This in turn aids the growth of the conjugated MAbs market.

The conjugated monoclonal antibodies market consists of the sales of conjugated monoclonal antibodies. Conjugated monoclonal antibodies are monoclonal antibodies associated with a chemotherapy drug or a radioactive particle. These are used in the treatment of cancer as they deliver the toxic substance directly to the tumor cells and reduce damage to normal cells in other parts of the body.

The conjugated monoclonal antibodies market covered in this report is segmented by drugs into adcetris, kadcyla. The conjugated monoclonal antibodies market is also segmented by technology into cleavable linker, non-cleavable linker and by application into blood cancer, breast cancer, ovarian cancer, lung cancer, brain tumour, others.

Read More On The Global Conjugated Monoclonal Antibodies Market Report:
https://www.thebusinessresearchcompany.com/report/conjugated-monoclonal-antibodies-global-market-report-2020-30-covid-19-growth-and-change

The global conjugated monoclonal antibodies market is expected to grow from $7.98 billion in 2020 to $8.55 billion in 2021 at a compound annual growth rate (CAGR) of 7.1%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The conjugated monoclonal antibody market size is expected to reach $11.43 billion in 2025 at a CAGR of 8%.

Major players in the antibody drug conjugate market are Pfizer Inc., F. Hoffmann-LA, Bristol -Myers Squibb, Merck & Co. Inc., Immunomedics Inc., Takeda Pharmaceuticals Industries Ltd., Daiichi Sankyo Company Limited, Actinium Pharmaceutical, Nordic Nanovector Inc., and Spectrum Pharmaceuticals Inc.

Conjugated Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030 is one of a series of new reports from The Business Research Company that provides conjugated monoclonal antibodies market overview, forecast conjugated monoclonal antibodies market size and growth for the whole market, conjugated monoclonal antibodies market segments, and geographies, conjugated monoclonal antibodies market trends, conjugated monoclonal antibodies market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request For A Sample Of The Global Conjugated Monoclonal Antibodies Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3424&type=smp

Here Is A List Of Similar Reports By The Business Research Company:
Monoclonal Antibodies (MAbs) Global Market Report 2021: COVID 19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-mabs-global-market-report

Biosimilar Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/biosimilar-monoclonal-antibodies-global-market-report-2020-30-covid-19-growth-and-change

Cancer Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/cancer-monoclonal-antibodies-global-market-report-2020-30-covid-19-growth-and-change

Biologics Global Market Report 2021: COVID-19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/biologics-global-market-report

Drugs for Immunotherapy Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/drugs-for-immunotherapy-global-market-report

Interested to know more about The Business Research Company?
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology. TBRC excels in company, market, and consumer research.

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn